The infections represent the most frequent complication in severe neutropenic patients undergoing high dose therapies supported by autologous or allogeneic bone marrow transplantation; dead related to infection is declining by the optimization of prophylaxis. We present two period under study in which prophylaxis was differentiated with the aim to show if the incidence of fungal infection could be correlated to the type of prophylaxis. From December 95 to November 97 patients undergoing high dose therapy received Ciprofloxacin 500mg two times a day, Nistatin 10000U and three times a day, Fluconazole 200mg a day i.v. and Acyclovir 500mg three times a day i.v.; from December 97 to March 2000 the same patients received Ciprofloxacin at the same dose, low dose Amphotericin-B 10mg i.v., Itraconazole 200mg a day, Acyclovir 500mg three times a day. 151 patients entered the first period and 171 patients the second period and they were matched for type of disease, sex, age and therapeutic modalities; 845 and 1320 blood coltural examinations were done in the two periods, respectively, mostly via central venous catheter. A positivity of blood cultures was recorded in 25% of tests performed; 8% of tests coming from the first period and 2.4% from the second period resulted positive for fungal infections, all for Candida. Candida parapsilosis was recorded only in the first period. No differences in bacterial infections were recorded among the two groups of patients under study; in particular 64.1% of positive tests resulted with Gram positive bacteria mostly Staphilococcus epidermidis and haemoliticus, 22.9% with Gram negative bacteria mostly Pseudomonas and Coli, fungal infections 12.9% of positive tests as total of both periods. The tolerance to low dose Amphotericin B i.v. was good with 4 interruptions of administration. Our conclusion is that the use of i.v. prophylaxis with Amphotericin B exerts a better prevention of fungal septicaemia in heavily treated patients with severe neutropenia. The major drawback of amphotericin B (AmB) is nephrotoxicity. During AmB treatment, we noted that a large decrease in serum potassium and magnesium was followed by a significant reduction in creatinine clearance and an increase in both serum urea and creatinine. Therefore, we surmised that potassium and magnesium supplements corresponding to the amounts lost by the kidneys, as well as vigorous hydration, are necessary to prevent renal function damage. Clinical study: AmB was administered to 61 septic severely ill hematooncological and/or BMT patients at a median dose of 0.9 mg/kg/day (0.51-1.29) for a median of 11 days (4-39). During therapy, serum electrolyte concentrations, biochemical parameters of renal function, and fluid balance were monitored frequently. The daily dosages of electrolytes corresponded to the potassium, magnesium and sodium lost via the kidneys. We did not wait for the development of serum electrolyte imbalances. Frequently, potassium was administered as a 7.5% KCl solution via a central venous catheter over 24 h using an infusion pump. All patients were hydrated to ensure a urine output of at least 3-4 litres per day. Providing this nephroprotective measures, the serum electrolytes (Na, K, and Mg), urea, and creatinine levels remained stable. Also the creatinine clearance did not change (median: 1.46 ml/s before AmB therapy vs. 1.59 ml/s after AmB, n.s.). However, we noted striking elevation of fractional excretion of Na (1.8% vs. 3.5%, p=0.05) and K (16.3% vs. 38.3%, p=0.002), starting very early after the beginning of AmB treatment, and leading to enormous wastes of these electrolytes into the urine (maximum: 501 mmol of K/day, 58.9 mmol of Mg/day, and 947 mmol of Na/day). It corresponded to enormous need of parenteral ion supplementation. Animal experiments: 16 male Wistar rats were given AmB 3,75 mg/kg intraperitonealy for 14-28 days. This led to severe nephrogenic diabetes insipidus (arginine-vasopressin test), marked increment in diuresis (median: 18 vs. 58 mL/day), and spontaneous increment in fluid intake (median: 32 vs. 74 mL/day). AmB treatment caused devastating changes in renal tubular system (light and electron microscopy), leaving the glomeruli relatively intact. Conclusion. These data strongly suggest that AmB therapy leads primarily to renal tubular and not glomerular damages and that decrease in glomerular filtration is largely and successfully preventable by vigorous hydration and ion supplementation S212
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